| Literature DB >> 36186775 |
Irene L Noronha1,2, Guilherme P Santa-Catharina1, Lucia Andrade1, Venceslau A Coelho3, Wilson Jacob-Filho3, Rosilene M Elias1.
Abstract
In the last decades, improvements in the average life expectancy in the world population have been associated with a significant increase in the proportion of elderly people, in parallel with a higher prevalence of non-communicable diseases, such as hypertension and diabetes. As the kidney is a common target organ of a variety of diseases, an adequate evaluation of renal function in the approach of this population is of special relevance. It is also known that the kidneys undergo aging-related changes expressed by a decline in the glomerular filtration rate (GFR), reflecting the loss of kidney function, either by a natural senescence process associated with healthy aging or by the length of exposure to diseases with potential kidney damage. Accurate assessment of renal function in the older population is of particular importance to evaluate the degree of kidney function loss, enabling tailored therapeutic interventions. The present review addresses a relevant topic, which is the effects of aging on renal function. In order to do that, we analyze and discuss age-related structural and functional changes. The text also examines the different options for evaluating GFR, from the use of direct methods to the implementation of several estimating equations. Finally, this manuscript supports clinicians in the interpretation of GFR changes associated with age and the management of the older patients with decreased kidney function.Entities:
Keywords: aging; elderly; estimated GFR; glomerular filtration rate (GFR); renal function; senescence
Year: 2022 PMID: 36186775 PMCID: PMC9519889 DOI: 10.3389/fmed.2022.769329
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Demographic characteristics, age ranges of study population, the corresponding changes of GFR, methods used to measure GFR.
|
|
| ||||
|---|---|---|---|---|---|
| Davies et al. ( | 70 healthy individuals | 100% male | 24–89 | GFR decline: from 122.8 to 65.3 mL/min/1.73 m2 (decreasing about 8 mL/min/1.73 m2 per decade) | Inulin clearance |
| Lindeman et al. ( | 254 healthy kidney subjects (non-proteinuric diabetes were included) | 98% american predominately white | 22–97 | Creatinine clearence decline: 0.75 ml/min per year | Creatinine clearance |
| Fuiano et al. ( | 26 living kidney donors | 100% males, young | 19–32 | GFR in young: 127 ± 5.8 mL/min/1.73 m2 | Inulin clearance |
| Rule et al. ( | 365 living kidney donors | 47.4% male, 80.3% white, age: | 18–71 | GFR decline: 4.9 mL/min/1.73 m2 per decade | Iothalamate clearance |
| Grewal et al. ( | 428 living kidney donors (241 aged > 40 yr) | 49.1% male | 40–73 | GFR decline: 0.91 mL/min/1.73 m2 per decade | 51Cr-EDTA clearance |
| Poggio et al. ( | 1,057 living kidney donors | 44% male, 11% African American | 38.5 ± 10.4 | GFR decline: 1.49 ± 0.61 ml/min/1.73 m2 per decade | 125I-Iothalamate clearance |
| Rule et al. ( | 1,203 adult living kidney donors | 42% male, 93% white | 18–77 | GFR decline: 6.3 mL/min/1.73 m2 per decade | Iothalamate clearance |
| Kasiske et al. ( | 201 kidney donors, 203 paired controls | 32% male | 43.1 ± 11.9 43.4 ± 11.3 | In kidney donors, GFR | Iohexol |
| Baba et al. ( | 75,521 healthy individuals | 47% male | 42.8 ± 10.4 | eGFR decline: 1.07 ± 0.42 ml/min/1.73 m2per year. | 3-variable Japanese equation |
| Pottel et al. ( | 633 living kidney donors | 36.8% male | 20–>70 | GFR decline: 0.89 ml/min/1.73 m2 per year | Inulin, iohexol, or 51Cr-EDTA |
| Eriksen et al. ( | 1,594 healthy individuals from the general population | 49% male 42% hypertension BMI:27.2 Kg/m2 | 50–62 | GFR decline: 0.95 ± 2.23 ml/min/1.73 m2 per year | Iohexol clearance |
| Waas et al. ( | 13,381 individuals from a German population cohort | 48.7% male 23.5% obese | 35–74 | eGFR decline: approximately 1 ml/min/1.73 m2 per year | eGFR calculated by CKD-EPI |
Figure 1Schematic structural and functional changes in the aging kidney.
Kidney functional changes with aging and declining GFR.
|
|
|---|
|
• Greater sensitivity to vasoconstrictor stimuli (angiotensin, norepinephrine and endothelin). |
Summary of studies addressing equations to estimate glomerular filtration rate and participation of older individuals.
|
|
|
|
|
|
|---|---|---|---|---|
| Levey et al. ( | MDRD | 125I-iothalamate | MDRD: more accurate than measured creatinine clearance (overestimates GFR by 19%) and | |
| Levey et al. ( | CKD-EPI | 125I-iothalamate | CKD-EPI: more accurate than MDRD. | |
| Schaeffner et al. ( | BIS 1 (creatinine) | Iohexol | BIS 2: lowest bias and smallest misclassification rate; | |
| Grubb et al. ( | CAPA | Inulin | Substandard P30 among the elderly (>80 years old) | |
| Björk et al. ( | LMR | Iohexol | Increased accuracy at measured GFR ≥90 mL/min/1.73 m2 | |
| Pottel et al. ( | FAS | Inulin, iohexol and iothalamate | Less biased and more accurate than CKD-EPI for older adults. |
MDRD, Modification of Diet in Renal Disease; CKD-EPI, Chronic Kidney Disease-Epidemiology Collaboration; BIS, Berlin Initiative Study; CAPA, Caucasian, Asian, Pediatric and Adult; LMR, Lund-Malmö revised creatinine equation; FAS, Full Age Spectrum.
Studies comparing discrepancies of GFR estimating equations and estimated creatinine clearance (Cockcroft–Gault) in older adults examining performances between the eGFR analyzed by metrics such as bias, precision, and accuracy.
|
|
|
|
| |
|---|---|---|---|---|
|
| 610 | 3,226 | 805 | 2,247 |
| Age (yr) | >70 | 70–89 | 74–93 | 65–90 |
| Cohort | The BIS cohort | 5 cohorts (Caucasian) | AGES-Reykjavik elderly cohort | Single center French cohort |
| Measured GFR | Plasma iohexol clearance | Plasma iohexol clearance | Plasma iohexol clearance | Inulin clearance |
| Cockcroft–Gault Cr | 2.53 (−4.06 to 9.21) | n.a | n.a | n.a |
| MDRDCr | 11.29 (3.85–17.68) | n.a | n.a | n.a |
| CKD-EPICr | 9.69 (2.45–15.49) | 3.6 (3.2–4.0) | 2.7 (2.1–3.3) | −2.0 (−3.0 to −1.0) |
| BIS-1 (Cr) | 0.80 (−5.03 to 6.11) | 1.7 (1.2–2.0) | n.a. | −2.0 (−3.5 to −1.5) |
| LMRCr | n.a | −0.7 (−1.0 to −0.4) | −4.8 (−5.4 to −4.2) | 2.0 (1.5–3.5) |
| FASCr | n.a | 0.6 (0.3–0.9) | −5.7 (−6.3 to −5.1) | 0.0 (−0.5 to 0.5) |
| CKD-EPICys | 2.05 (−3.23 to 8.61) | −2.7 (−3.1 to −2.3) | n.a | n.a |
| FASCys | n.a | −1.1 (−1.6 to −0.8) | n.a | n.a |
| CAPA (Cys) | n.a | −1.4 (−1.8 to −1.0) | n.a | n.a |
| CKD-EPICr+Cys | n.a | −0.1 (−0.4 to 0.2) | 0.6 (−0.1 to 1.2) | n.a |
| BIS-2 (Cr+Cys) | 0.87 (−4.40 to 4.98) | −1.2 (−1.5 to −0.8) | n.a | n.a |
| MEANLMR+CAPA | n.a | −1.0 (−1.3 to −0.6) | −2.7 (−3.2 to −2.1) | n.a |
| FASCr+Cys | n.a | −0.8 (−1.1 to −0.5) | −5.9 (−6.5 to −5.4) | n.a |
| CKD-EPICr | n.a | 12.3 (11.9–13.0) | 12.1 (11.2–13.4) | 15.0 (14.5–17.0) |
| BIS-1 (Cr) | n.a | 11.6 (11.1–12.1) | n.a | 15.0 (14.0–16.5) |
| LMRCr | n.a | 10.5 (10.1–11.0) | 10.8 (10.1–11.5) | 14.0 (13.0–15.5) |
| FASCr | n.a | 11.1 (10.6–11.5) | 10.7 (9.9–11.9) | 14.0 (12.5–15.0) |
| CKD-EPICys | n.a | 11.8 (11.3–12.5) | n.a | n.a |
| FASCys | n.a | 12.2 (11.7–12.8) | n.a | n.a |
| CAPA (Cys) | n.a | 11.9 (11.3–12.6) | n.a | n.a |
| CKD-EPICr+Cys | n.a | 10.2 (9.6–10.8) | 10.2 (9.0–11.1) | n.a |
| BIS-2 (Cr+Cys) | n.a | 10.5 (10.0–11.0) | n.a | n.a |
| MEANLMR+CAPA | n.a | 9.2 (8.8–9.6) | 9.3 (8.5–10.1) | n.a |
| FASCr+Cys | n.a | 10.1 (9.7–10.7) | 10.0 (9.1–10.9) | n.a |
| Cockcroft–GaultCr | 87.4 | n.a | n.a | n.a |
| MDRDCr | 70.9 | n.a | n.a | n.a |
| CKD-EPICr | 77.9 | 76.4 (74.9–77.9) | 91.7 (89.9–93.4) | 77.0 (73.0–80.0) |
| BIS-1 (Cr) | 95.1 | 77.5 (76.1–78.9) | n.a. | 76.0 (72.5–79.5) |
| LMRCr | n.a | 83.5 (82.2–84.8) | 95.0 (93.5–96.5) | 80.0 (76.5–83.5) |
| FASCr | n.a | 80.9 (79.5–82.3) | 95.8 (94.4–97.2) | 78.5 (75.0–82.0) |
| CKD-EPICys | 89.1 | 78.8 (77.3–80.4) | n.a | n.a |
| FASCys | n.a | 80.9 (79.4–82.4) | n.a | n.a |
| CAPA (Cys) | n.a | 80.3 (78.8–81.8) | n.a | n.a |
| CKD-EPICr+Cys | 86.8 (85.5–88.1) | 96.1 (94.8–97.4) | n.a | |
| BIS-2 (Cr+Cys) | 96.1 | 85.7 (84.4–87.0) | n.a | n.a |
| MEANLMR+CAPA | n.a | 88.7 (87.5–89.9) | 97.3 (96.2–98.4) | n.a |
| FASCr+Cys | n.a | 85.7 (84.4–87.1) | 97.8 (96.7–98.8) | n.a |
Significantly worse (P < 0.05) than corresponding CKD-EPI equation.
Significantly better (P < 0.05) than corresponding CKD-EPI equation.
No statistical difference (P < 0.05) compared with corresponding CKD-EPI equation.